SG11202108734VA - Anti-trem2 antibodies and methods of use thereof - Google Patents
Anti-trem2 antibodies and methods of use thereofInfo
- Publication number
- SG11202108734VA SG11202108734VA SG11202108734VA SG11202108734VA SG11202108734VA SG 11202108734V A SG11202108734V A SG 11202108734VA SG 11202108734V A SG11202108734V A SG 11202108734VA SG 11202108734V A SG11202108734V A SG 11202108734VA SG 11202108734V A SG11202108734V A SG 11202108734VA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- trem2 antibodies
- trem2
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962808141P | 2019-02-20 | 2019-02-20 | |
| PCT/US2020/019093 WO2020172450A1 (en) | 2019-02-20 | 2020-02-20 | Anti-trem2 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108734VA true SG11202108734VA (en) | 2021-09-29 |
Family
ID=69844940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108734VA SG11202108734VA (en) | 2019-02-20 | 2020-02-20 | Anti-trem2 antibodies and methods of use thereof |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20220119522A1 (en) |
| EP (1) | EP3927743A1 (en) |
| JP (1) | JP2022520868A (en) |
| KR (1) | KR20210135518A (en) |
| CN (1) | CN113614110A (en) |
| AR (1) | AR118144A1 (en) |
| AU (1) | AU2020226754A1 (en) |
| BR (1) | BR112021015656A2 (en) |
| CA (1) | CA3130086A1 (en) |
| CL (1) | CL2021002206A1 (en) |
| CO (1) | CO2021012230A2 (en) |
| EA (1) | EA202192294A1 (en) |
| EC (1) | ECSP21069105A (en) |
| IL (1) | IL285651A (en) |
| MA (1) | MA55025A (en) |
| MX (1) | MX2021009722A (en) |
| PE (1) | PE20211979A1 (en) |
| SG (1) | SG11202108734VA (en) |
| TW (1) | TW202045543A (en) |
| WO (2) | WO2020172457A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (en) | 2017-04-21 | 2019-10-20 | Amgen Inc | Trem2 antigen binding proteins and uses thereof |
| IL294655A (en) | 2020-01-13 | 2022-09-01 | Denali Therapeutics Inc | Anti-trem2 antibodies and methods of use thereof |
| TW202306993A (en) * | 2021-05-14 | 2023-02-16 | 美商建南德克公司 | Agonists of trem2 |
| WO2023164516A1 (en) | 2022-02-23 | 2023-08-31 | Alector Llc | Methods of use of anti-trem2 antibodies |
| WO2023192288A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| WO2023192282A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10087408B2 (en) | 2010-07-07 | 2018-10-02 | The University Of British Columbia | System and method for microfluidic cell culture |
| US9188593B2 (en) | 2010-07-16 | 2015-11-17 | The University Of British Columbia | Methods for assaying cellular binding interactions |
| MX2017001531A (en) * | 2014-08-08 | 2017-05-15 | Alector Llc | Anti-trem2 antibodies and methods of use thereof. |
| JP6996979B2 (en) * | 2015-03-31 | 2022-02-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Antigen-binding molecule containing trimer TNF family ligand |
| WO2017058866A1 (en) * | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| CN117069841A (en) * | 2015-10-06 | 2023-11-17 | 艾利妥 | anti-TREM 2 antibodies and methods of use thereof |
| JOP20190248A1 (en) | 2017-04-21 | 2019-10-20 | Amgen Inc | Trem2 antigen binding proteins and uses thereof |
| BR112019022752A2 (en) | 2017-08-03 | 2020-05-19 | Alector Llc | anti-train2 antibodies and methods of using them |
-
2020
- 2020-02-20 CN CN202080015804.2A patent/CN113614110A/en active Pending
- 2020-02-20 EA EA202192294A patent/EA202192294A1/en unknown
- 2020-02-20 AR ARP200100461A patent/AR118144A1/en unknown
- 2020-02-20 PE PE2021001367A patent/PE20211979A1/en unknown
- 2020-02-20 MA MA055025A patent/MA55025A/en unknown
- 2020-02-20 KR KR1020217028927A patent/KR20210135518A/en unknown
- 2020-02-20 CA CA3130086A patent/CA3130086A1/en active Pending
- 2020-02-20 JP JP2021548668A patent/JP2022520868A/en active Pending
- 2020-02-20 TW TW109105560A patent/TW202045543A/en unknown
- 2020-02-20 EP EP20711737.5A patent/EP3927743A1/en active Pending
- 2020-02-20 MX MX2021009722A patent/MX2021009722A/en unknown
- 2020-02-20 BR BR112021015656-9A patent/BR112021015656A2/en unknown
- 2020-02-20 SG SG11202108734VA patent/SG11202108734VA/en unknown
- 2020-02-20 WO PCT/US2020/019104 patent/WO2020172457A1/en active Application Filing
- 2020-02-20 WO PCT/US2020/019093 patent/WO2020172450A1/en unknown
- 2020-02-20 AU AU2020226754A patent/AU2020226754A1/en active Pending
-
2021
- 2021-08-16 IL IL285651A patent/IL285651A/en unknown
- 2021-08-16 US US17/402,986 patent/US20220119522A1/en active Pending
- 2021-08-16 US US17/403,406 patent/US20220073609A1/en active Pending
- 2021-08-18 CL CL2021002206A patent/CL2021002206A1/en unknown
- 2021-09-17 EC ECSENADI202169105A patent/ECSP21069105A/en unknown
- 2021-09-17 CO CONC2021/0012230A patent/CO2021012230A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP21069105A (en) | 2021-11-18 |
| EP3927743A1 (en) | 2021-12-29 |
| WO2020172457A1 (en) | 2020-08-27 |
| IL285651A (en) | 2021-09-30 |
| WO2020172450A1 (en) | 2020-08-27 |
| AR118144A1 (en) | 2021-09-22 |
| CO2021012230A2 (en) | 2021-09-30 |
| BR112021015656A2 (en) | 2021-10-05 |
| AU2020226754A1 (en) | 2021-09-16 |
| MA55025A (en) | 2021-12-29 |
| CA3130086A1 (en) | 2020-08-27 |
| TW202045543A (en) | 2020-12-16 |
| US20220073609A1 (en) | 2022-03-10 |
| JP2022520868A (en) | 2022-04-01 |
| KR20210135518A (en) | 2021-11-15 |
| PE20211979A1 (en) | 2021-10-05 |
| EA202192294A1 (en) | 2021-12-24 |
| US20220119522A1 (en) | 2022-04-21 |
| CL2021002206A1 (en) | 2022-04-22 |
| MX2021009722A (en) | 2021-09-14 |
| CN113614110A (en) | 2021-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276731A (en) | Anti-cd73 antibodies and methods of use thereof | |
| IL278821A (en) | Anti-sirpa antibodies and methods of use thereof | |
| SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
| HUE062927T2 (en) | Anti-tigit antibodies and methods of use thereof | |
| HUE062436T2 (en) | Anti-trem2 antibodies and methods of use thereof | |
| IL270214A (en) | Anti-sortilin antibodies and methods of use thereof | |
| EP3852805A4 (en) | Anti-lilrb2 antibodies and methods of use thereof | |
| SG11202108398YA (en) | Anti-claudin 18 antibodies and methods of use thereof | |
| IL279648A (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
| IL290741A (en) | Anti-cd96 antibodies and methods of use thereof | |
| IL277212A (en) | Anti-klk5 antibodies and methods of use | |
| SG11202108734VA (en) | Anti-trem2 antibodies and methods of use thereof | |
| IL287282A (en) | Anti-mertk antibodies and their methods of use | |
| IL289952A (en) | Anti-ms4a4a antibodies and methods of use thereof | |
| IL289829A (en) | Immunomodulatory antibodies and methods of use thereof | |
| IL285401A (en) | Anti-clec2d antibodies and methods of use thereof | |
| IL283884A (en) | Anti-il-36 antibodies and methods of use thereof | |
| IL280338A (en) | Anti-siglec-5 antibodies and methods of use thereof | |
| IL291461A (en) | Anti-alpha-synuclein antibodies and methods of use thereof | |
| IL282424A (en) | Alk2 antibodies and methods of use thereof | |
| IL274221A (en) | Anti-apoc3 antibodies and methods of use thereof | |
| IL288886A (en) | Antibodies and methods of use | |
| EP3746484A4 (en) | Anti-ms4a6a antibodies and methods of use thereof | |
| IL279227A (en) | Anti-siglec-7 antibodies and methods of use thereof | |
| SG11202113221RA (en) | Anti-cd137l antibodies and methods of using same |